Omnicell, Inc. (OMCL) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Technology / Software · as of Sep 25, 2026
Omnicell, Inc. (OMCL)
A forensic read on Omnicell, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
3.5
Distress distance
Clean
Earnings quality
3
Forensic signals
37.6
P / E (ttm)
0.2%
ROE
$1.5B
Market cap
6.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Omnicell, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.5, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
0.3%
FY2025
Return on invested capital.Return on invested capital is 0.3% in the latest fiscal year and rising across FY2023–FY2025 from -2.0%. After-tax operating profit was ($28M) in FY2023 and $3M in FY2025, with operating income at -3.0% of revenue in FY2023, 0.0% in FY2024 and 0.4% in FY2025. The capital base behind it barely moved across FY2023–FY2025 ($1.4B to $1.3B, -6%), so there has been little new capital for that return to be earned on. FY2023's operating profit carried a $16M restructuring charge that took about 0.9 points off that year's return, and FY2025's carried a $7M restructuring charge that took about 0.3 points off the latest; so, net of each other, the two charges add about 0.6 points to the +2.3-point change across FY2023–FY2025.
+1.3%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +3% over the last 2 years to FY2025 (+1.3%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~2%.
+16.9%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +16.9% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by payables paid down 15% against +6% in cost of sales and inventory up +14% against +6% in cost of sales. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 13% of net operating assets, against an accruals ratio of 16.9%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
Key fundamentals
Latest Revenue$1.18B
Revenue Growth YoY+6.5%
Revenue CAGR (2yr)+1.6%
Net Margin0.2%
Free Cash Flow$86.9M
Return on Equity0.2%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Omnicell, Inc.'s actual 10-K/10-Q/8-K filings?